Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.

Int J Rheumatol · 2011 · PMC3195539 · PMID 22013450

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

did not reach statistical significanceP = 0.073so close (0.05 < p ≤ 0.1)

More imatinib-treated patients discontinued study because of perceived drug-related AEs although this did not reach statistical significance (imatinib: 13 versus placebo: 6; P = 0.073).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.